73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics

Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine. His scientific expertise includes biomedical engineering and drug delivery, computational modeling, pharmacology, clinical strategy and translational medicine. Prior to joining Verve, Dr. Bellinger co-founded and served as chief scientific officer of Lyndra Therapeutics, where he helped to build the company’s research team and was involved in the company’s key partnerships with Gilead and Allergan. During Dr. Bellinger’s tenure, Lyndra advanced several programs into the clinic. Prior to Lyndra, Dr. Bellinger served as chief scientific officer of Cocoon Biotech, leading the development of the company’s drug delivery platform based on silk fibroin. Dr. Bellinger completed his clinical training in internal medicine at the University of California, San Francisco, and his clinical training in cardiology at Brigham and Women’s Hospital. He completed his postdoctoral research training in drug delivery with Dr. Robert Langer at the Massachusetts Institute of Technology. Dr. Bellinger holds an M.D. and Ph.D. from Columbia University, an M.S. in mathematics from New York University, and an A.B. in physics from Princeton University.